Tiziana Life Sciences (TILS)
TILS Share PerformanceMore
|52 week high||240.00 25/04/17|
|52 week low||102.05 08/06/17|
|52 week change||-40.60 (-21.38%)|
|4 week volume||72,966 27/09/17|
Latest News« previous» nextMore
29/09/2017 - 07:00 RNS
RNS Number: 1613S Tiziana Life Sciences PLC 29 September 2017 Tiziana Life Sciences plc ("Tiziana" or "the Company") Interim Results for the Six Months Ended 30 June 2017 Advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet need London, 29 September 2017 - Tiziana Life Sciences plc ("Tiziana", A...
06/09/2017 - 07:08 StockMarketWire
Tiziana Life Sciences announced the development of a novel, proprietary, oral formulation of foralumab, a fully human ...
06/09/2017 - 07:00 RNS
RNS Number: 8848P Tiziana Life Sciences PLC 06 September 2017 Tiziana Life Sciences plc ("Tiziana" or the "Company") Development of a Proprietary Oral Formulation of Foralumab, a Fully Human Anti-CD3 mAb, for use in an Upcoming Phase 2a Clinical Trial in NASH Successfully developed a novel formulation enabling oral immunotherapy with foraluma...
31/08/2017 - 11:07 RNS
RNS Number: 4431P Tiziana Life Sciences PLC 31 August 2017 Tiziana Life Sciences PLC ("Tiziana" or the "Company") Grant of options - Director's dealing London, 31 August 2017 - Tiziana Life Sciences plc (AIM: TILS, the "Company"), the clinical stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, announces that ...
16/08/2017 - 08:19 StockMarketWire
Tiziana Life Sciences, a clinical stage biotechnology company, said holders of the company's convertible loan note (CLN) h...
16/08/2017 - 07:00 RNS
RNS Number: 0883O Tiziana Life Sciences PLC 16 August 2017 Tiziana Life Sciences plc ("Tiziana" or the "Company") Conversion of outstanding loan notes, amendment of warrant terms and issue of equity London, August 16, 2017 - Tiziana Life Sciences plc ("Tiziana", AIM: TILS), a clinical stage biotechnology company developing targeted drugs for cancer and aut...
28/07/2017 - 07:00 RNS
RNS Number: 3714M Tiziana Life Sciences PLC 28 July 2017 Tiziana Life Sciences plc ("Tiziana" or the "Company") Publication of Research Article on Foralumab, a Fully Human Anti-CD3 Antibody Being Developed as an Oral Therapy for NASH and Autoimmune Diseases Foralumab (NI-0401) is a unique oral therapy that stimulates the gut immune system and ...
19/07/2017 - 07:14 StockMarketWire
Tiziana Life Sciences announced the enrolment of the first patient in its Phase IIa clinical trial with milciclib, a novel inhib...
|Dividend yield||0 %|
Latest discussion posts More
“Bad news this am but couldn't resist a 500 top up at 115.06.”▼
“Beaufort Securities's note out this morning on Research Tree: "Tiziana progressed well during the FY2015. It strengthened its portfolio by acquiring exclusive licence for both ...”▼
“With sp @110 and bid @ 115 I tried buying 2500 online at Barclays. Quoted 187.4 Obviously buying is being discouraged for whatever reason”▼
Codes & Symbols
|Symbols||TILS, LSE:TILS, TILS.L, TILS:LN, LON:TILS, XLON:TILS|